Loading...

RANI RANI THERAPEUTICS HOLDINGS INC Investments/Divestments 8-K Filing

RN T

RN

RANI THERAPEUTICS HOLDINGS INC

(RANI)

2023 8-K

Financial Update

Governance Changes

Financial Update

Major Financing Event

Financial Statements

Equity Offerings

Notification of Non-Compliance

Financial Statements

Nasdaq Compliance

Financial Results

Financial Results

Securities Offering

Earnings Reports

Securities Purchase Agreement

Equity Financing Decision

Collaboration Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Earnings Reports

Clinical Trial Results

Stock Option Repricing

Preclinical Data and Clinic...

Earnings Reports

Lease Agreement and Restruc...

Preclinical Data Announcement

Drug Delivery Results

Financial Results Announcement

License and Supply Agreement

Earnings Reports

Departure of Directors

Results of Operations and F...

License and Supply Agreement

Financial Condition

External Links:

Rani Therapeutics Holdings, Inc. entered into a License and Supply Agreement with Celltrion, Inc. for the exclusive rights to manufacture, develop, and commercialize an orally-administered therapeutic product using Celltrion's ustekinumab biosimilar.

AI Assistant

RANI THERAPEUTICS HOLDINGS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.